Eli Lilly and Company’s Global PK/PD and Pharmacometrics Departmen=
t is looking for enthusiastic new or experienced scientists.
Are you ready to join a dedicated team at Lilly working to improve lives of=
patients? The scientists in the department of PK/PD & Pharmacometrics are =
involved in research and development throughout the value chain from precli=
nical lead molecule identification to clinical post-drug approval with the =
goal of identifying and developing the right drug with the right dose for t=
he right patient using model-informed drug research and development approac=
hes. Do you have the scientific and technical expertise to influence and ap=
ply model-based drug discovery and development? Can you communicate effecti=
vely with confidence, and network internally and externally? Our organizati=
on is looking for a dynamic scientist who will, through application of PK/P=
D and pharmacometrics approaches, including quantitative disease modeling, =
drug-disease modeling and simulation, data mining and literature modeling, =
and associated simulations, be able to
- Provide PKPD scienti=
fic leadership to project teams to support the selection of the right targe=
t, molecule, dose, patient population and development strategies. You will =
apply the appropriate pharmacometric approaches to translate preclinical to=
clinical and integrate data from multiple disciplines.
- Expect and understan=
d the high level issues affecting the drug discovery/development and help d=
erive effective solutions. Support decision-making through partnership and =
collaboration with cross-functional teams.
- Develop PK/PD sectio=
ns of program and product team plans as project leader.
- Lead and support the=
preparation and delivery of Phase I, II, and III study protocols, analysis=
plans, data interpretation and study reports.
- Responsible for prep=
aration of relevant INDs, IBs, CTDs and other regulatory documents for deve=
lopment and registration of new drugs and line extensions. This may involve=
direct interaction with FDA, EMA, PMDA and other regulatory agencies.
- Provide coaching and=
mentoring to other scientists within the division and in other disciplines=
as well as interact, teach and collaborate with academia.
- Represent the group =
to increase visibility externally, through key publications, active leaders=
hip in key scientific organizations, industry trade groups or consortia.
In this role you will have opportunities to contribute to developing strate=
gy, setting direction for the organization, and drive successful implementa=
tion of the strategy to produce results.
At Lilly, we unite caring with discovery to make life better for people aro=
und the world. We are a global healthcare leader headquartered in Indianapo=
lis, Indiana. Our 39,000 employees around the world work to discover and br=
ing life-changing medicines to those who need them, improve the understandi=
ng and management of disease, and give back to our communities through phil=
anthropy and volunteerism. We give our best effort to our work, and we put =
people first. We’re looking for people who are determined to make l=
ife better for people around the world.
- PhD and/or MD in rel=
evant scientific field such as pharmaceutical sciences or pharmacokinetics
- While Experience fro=
m industry, regulatory, consulting or academia with exposure to industry is=
preferred, we are also looking for enthusiastic new graduates
Lilly is an EEO/Affirmative Action Employer and does not discriminat=
e on the basis of age, race, color, religion, gender, sexual orientation, g=
ender identity, gender expression, national origin, protected veteran statu=
s, disability or any other legally protected status.
If you’re interested, please apply at https://careers.lilly.com/job=
Brian A. Willis, PhD
Principal Research Scientist, PK/PD and Pharmacometrics
Eli Lilly and Company
Lilly Corporate Center, Indianapolis IN 46285 USA
317.651.1308 (office) | 317.220.9191 (mobile)
CONFIDENTIALITY NOTICE: This e-mail message (including all attachments) is =
for the sole use of the intended recipient(s) and may contain confidential =
and privileged information. Any unauthorized review, use, disclosure, copyi=
ng or distribution is strictly prohibited. If you are not the intended reci=
pient, please contact the sender by reply e-mail and destroy all copies of =
the original message.
Received on Thu May 31 2018 - 10:44:57 EDT